Ozen, Ahmet http://orcid.org/0000-0002-9065-1901
Kasap, Nurhan
Vujkovic-Cvijin, Ivan http://orcid.org/0000-0002-8611-4900
Apps, Richard
Cheung, Foo
Karakoc-Aydiner, Elif
Akkelle, Bilge
Sari, Sinan
Tutar, Engin
Ozcay, Figen
Uygun, Dilara Kocacik
Islek, Ali
Akgun, Gamze
Selcuk, Merve
Sezer, Oya Balci
Zhang, Yu
Kutluk, Gunsel
Topal, Erdem
Sayar, Ersin
Celikel, Cigdem
Houwen, Roderick H. J.
Bingol, Aysen
Ogulur, Ismail
Eltan, Sevgi Bilgic
Snow, Andrew L.
Lake, Camille
Fantoni, Giovanna
Alba, Camille
Sellers, Brian
Chauvin, Samuel D. http://orcid.org/0000-0003-0232-751X
Dalgard, Clifton L.
Harari, Olivier
Ni, Yan G.
Wang, Ming-Dauh
Devalaraja-Narashimha, Kishor
Subramanian, Poorani http://orcid.org/0000-0003-4371-7290
Ergelen, Rabia
Artan, Reha
Guner, Sukru Nail
Dalgic, Buket
Tsang, John
Belkaid, Yasmine http://orcid.org/0000-0001-9962-3571
Ertem, Deniz
Baris, Safa
Lenardo, Michael J. http://orcid.org/0000-0003-1584-468X
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (HHSN316201300006W/HHSN27200002)
Marmara Üniversitesi (SAG-C-TUP-230119-0018)
Turkish National Society of Allergy and Clinical Immunology
Article History
Received: 18 June 2020
Accepted: 28 October 2020
First Online: 4 January 2021
Competing interests
: The authors M.J.L. and A.O. have a pending patent on C5 inhibitor treatment of CHAPLE. B.S. is a former SomaLogic, Inc. (Boulder, CO, USA) employee and a company shareholder. O.H., Y.G.N., M.-D.W. and K.D.-N. are employees of Regeneron Pharmaceuticals Inc., a biopharma company. There are no conflicts of interest to report for the remaining coauthors.